Company intelligence / Profile preview
Reunion Neuroscience
Philadelphia, Pennsylvania, United Statesreunionneuro.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
A clinical-stage biopharmaceutical company developing serotonergic psychedelic therapeutics. Lead candidate RE104 is a short-duration prodrug of psilocybin-like compound in Phase II trials for PPD and AjD. Recently raised $103M Series A to advance clinical programs.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesSerotonergic neuroplastogens
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
partner_name: Fluence, type:Therapy training collaborationpartner_name: Metamorph AI, type:AI-powered therapy tools
Beyond the preview
Go deeper on Reunion Neuroscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reunion Neuroscience.